cant advances in clinical management and care, over half of patients aged ≥45 years (52% of men and 56% of women) will die within 5 years of a stroke. 1 About 60% of stroke survivors will recover functional independence within 3 months of onset whereas 20% will require institutional care. 1 Alarmingly, stroke-related morbidity implies tremendous costs, with an annual European expenditure of E64.1 billion in 2010 alone, 4 as well as a heavy burden for individuals, families, and society. Breakthrough therapies have yet to be approved and there are still no highly effective acute treatments available. Over the past 20 years, clinical research has focused on the development of reperfusion therapies for acute ischaemic stroke, including systemic i.v. thrombolytics as well as endovascular reperfusion therapies including intra-arterial thrombolysis, mechanical thrombectomy, and thromboaspiration.
5 I.v. thrombolysis with tissue plasminogen activator (tPA) remains the only evidence-based treatment for acute ischaemic stroke. 1 A major trade-off of reperfusion therapies is that restoration of blood flow paradoxically acts as an amplifier of cerebral post-ischaemic injury, a phenomenon which may explain why many stroke patients do not recover despite effective recanalization of the occluded artery. 6 Cerebral reperfusion injury is characterized by a detrimental cascade of molecular events leading to leucocyte infiltration, platelet and complement activation, post-ischaemic hyperperfusion, and breakdown of the blood -brain barrier (BBB). 6 In this setting, overproduction of reactive oxygen species (ROS) plays a major role. 7 Restoration of blood flow following ischaemic stroke enables ROS accumulation, which rapidly exhaust endogenous antioxidant capacity, favouring mitochondrial disruption and cellular death. 7 A growing body of evidence indicates that individual cell components within the BBB play unique and cumulative roles, leading to irreversible cerebral damage. 8 Activation of oxidant pathways in endothelial cells triggers the expression of matrix metalloproteinases (MMPs), degradation of tight junction proteins, and subsequent leakage of the BBB. Impairment of the BBB, in turn, exacerbates intravascular thrombosis and extravasation, as the result of platelet activation and increased vascular permeability. 6, 9 Loss of endothelial integrity is a major factor implicated in the transition from ischaemic to haemorrhagic stroke, and accounts for worse prognosis.
5
Although previous work has provided key insights into ROS-driven BBB disruption, we currently lack a detailed understanding of how redox pathways are interconnected in the aetiology of cerebral postischaemic injury. A better characterization of the molecular sources underpinning free radical generation may foster mechanism-based therapeutic strategies to combat stroke and its complications. The mammalian adaptor p66 Shc is emerging as part of a key transduction pathway relevant to oxidative stress and endothelial damage. 10 This protein functions as a redox enzyme implicated in mitochondrial ROS generation and translation of oxidative signals into apoptosis. 10 Several chronic stimuli trigger p66 Shc phosphorylation, allowing transfer of the protein from the cytosol to the mitochondrion where it catalyses ROS production via cytochrome c oxidation. 16 Indeed, p66 Shc -/ -mice displayed a significantly reduced stroke size, preserved neurological function, and decreased production of free radicals. 16 The validity of these findings is supported by the employment of a genetic approach which has the unique advantage of providing reliable read-outs on the role of p66
Shc during I/R injury. 16 They also found that reperfusion injury in wildtype mice induced p66 Shc up-regulation in the basilar and middle cerebral artery, but not in brain tissue, suggesting a predominant Figure 1 Role of the adaptor p66
Shc in post-ischaemic cerebral damage. Post-ischaemic reperfusion causes p66 Shc phosphorylation at Ser36 which, in turn, triggers NADPH oxidase activity. These molecular events favour generation of free radicals leading to down-regulation of the tight junction protein claudin-5, loss of endothelial integrity with subsequent extravasation and platelet activation. Targeting p66 Shc by small interfering RNA (siRNA) is able to prevent this detrimental chain of events. ROS, reactive oxygen species; NADPH oxidase, nicotinamide adenine dinucleotide phosphate-oxidase; BBB, blood-brain barrier.
Editorial involvement of vascular p66 Shc . 16 In their current study, 12 17 Taken together, the findings reported so far suggest that activation of p66 Shc in the brain vasculature is likely to be identified as a key driver of post-ischaemic cerebral damage rather than a compensatory and perhaps futile mechanism counteracting neuronal damage ( Figure 1) . Another interesting implication of the present work is that p66
Shc expression might serve as a potential biomarker to monitor I/R injury in humans. 12 Data collected in peripheral blood monocytes isolated from stroke patients showed that p66 Shc expression levels were transiently increased 6 h after initial stroke symptoms and returned to control levels after 24 h. Based on these results, one can postulate that p66 Shc up-regulation may be useful in identifying patients with ongoing cerebral ischaemia, especially when clinical presentation remains obscure due to the lack of specific symptoms. Further studies are needed to understand the significance of p66 Shc up-regulation in peripheral monocytes and its reliability as a potential biomarker in this area. Undoubtedly, the work by Spescha et al. is a good example of translational research linking basic findings to the clinical setting. The present results contribute to building a solid ground for a 'lab to market' approach addressing whether p66 Shc can be considered as a novel molecular target and/or a diagnostic tool in patients with ischaemic stroke.
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